Исходы, сообщаемые пациентами, при деинтенсификации сложных режимов инсулинотерапии сахарного диабета 2 типа

В современной диабетологии растет интерес к исходам, сообщаемым пациентами (ИСП), как важному показателю, влияющему на эффективность терапии. В представленном обзоре анализируется влияние деинтенсификации сложных режимов инсулинотерапии с использованием препарата иГларЛикси (комбинации инсулина гларгин 100 Ед/мл и ликсисенатида) на качество жизни и удовлетворенность лечением пациентов с сахарным диабетом 2 типа (СД2). Рассмотрены результаты ключевых исследований (SoliSwitch, IDEAL, SIMPLIFY Japan), демонстрирующих значительное улучшение показателей ИСП при переходе с многократных инъекций инсулина или готовых смесей на однократное введение иГларЛикси. Наиболее выраженные улучшения отмечены в доменах «бремя лечения» и «управление диабетом». С учетом влияния психосоциальных факторов на восприятие терапии и приверженность лечению деинтенсификация инсулинотерапии может быть особенно значима для пациентов, испытывающих стигматизацию и диабетический дистресс. Результаты обзора подтверждают, что перевод пациентов на иГларЛикси является эффективной стратегией деинтенсификации, улучшающей как гликемический контроль, так и качество жизни при СД2.

1. Holmes-Truscott E, Browne JL, Ventura AD et al. Diabetes stigma is associated with negative treatment appraisals among adults with insulin-treated type 2 diabetes: Results from the second Diabetes MILES – Australia (MILES-2) survey. Diabetic Med. 2018; 35(5): 658–62. doi: 10.1111/dme.13598.

2. Wagner JA, Tennen H, Feinn R, Osborn CY. Self-reported discrimination, diabetes distress, and continuous blood glucose in women with type 2 diabetes. J Immigr Minor Health. 2015; 17(2): 566–73. doi: 10.1007/s10903-013-9948-8.

3. Baucom KJ, Queen TL, Wiebe DJ et al. Depressive symptoms, daily stress, and adherence in late adolescents with type 1 diabetes. Health Psychology. 2015; 34(5): 522–30. doi: 10.1037/hea0000219.

4. Amin MF, Bhowmik B., Rouf R. et al. Assessment of quality of life and its determinants in type-2 diabetes patients using the WHOQOL-BREF instrument in Bangladesh. BMC Endocr Disord. 2022; 22(1): 162. doi: 10.1186/s12902-022-01072-w.

5. Cho MK, Kim MY. What affects quality of life for people with type 1 diabetes?: A cross-sectional observational study. Int J Environ Res Public Health. 2021; 18(14): 7623. doi: 10.3390/ijerph18147623.

6. Alvarado-Martel D, Velasco R, Sanchez-Hernandez RM et al. Quality of life and type 1 diabetes: A study assessing patients' perceptions and self-management needs. Patient Prefer Adherence. 2015; 9: 1315–23. doi: 10.2147/PPA.S87310.

7. Tamornpark R, Utsaha S, Apidechkul T et al. Quality of life and factors associated with a good quality of life among diabetes mellitus patients in northern Thailand. Health Qual Life Outcomes. 2022; 20(1): 81. doi: 10.1186/s12955-022-01986-y.

8. Fadini GP, Ciardullo S, Perseghin G et al. Preferences, expectations and attitudes on basal insulin from patient-physician-payer perspective: A multi-stakeholder survey by the Italian Diabetes Society (ITA4P Study). Diabetes Ther. 2025; 16(1): 123–30. doi:10.1007/s13300-025-01729-4.

9. Ishii H, Kamiya H, Takahashi Y, Morimoto Y, Yabe D. Quality of life in Japanese people with type 2 diabetes switching from multiple daily insulin injections to once-daily iGlarLixi: SIMPLIFY Japan. Diabetes Ther. 2024; 15(11): 2381–400. doi:10.1007/s13300-024-01645-z.

10. Haluzík M, Cypryk K, Alvarez A et al. Efficacy and safety of switching to iGlarLixi from premixed insulins in people with type 2 diabetes: The Soli-SWITCH study. Diabetes Obes Metab. 2025; 27(5): 2730–39. doi:10.1111/dom.16276.

11. Brod M, Christensen T, Hammer M et al. Examining the ability to detect change using the TRIM-Diabetes and TRIM-Diabetes Device measures. Qual Life Res. 2011; 20(9): 1513–18. doi: 10.1007/s11136-011-9886-7.

12. Polonsky WH. Improved patient- and physician-reported outcomes with iGlarLixi when switching from premixed insulin in people with type 2 diabetes (T2D): The Soli-Switch study. Short oral on poster presentation at: 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025); March 20, 2025. Amsterdam, Netherlands.

13. Polonsky WH, Giorgino F, Rosenstock J et al. Improved patient-reported outcomes with iGlarLixi versus premix BIAsp 30 in people with type 2 diabetes in the SoliMix trial. Diabetes Obes Metab. 2022; 24(12): 2364–72. doi: 10.1111/dom.14822.

14. Zizka O. Insulin therapy de-intensification with iGlarLixi (IDEAL) randomised controlled trial: Patient-reported outcomes. Oral presentation at: 18th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2025). March 21, 2025. Amsterdam, Netherlands.

15. Bradley C. The Diabetes Treatment Satisfaction Questionnaire: DTSQ. In Bradley C (Ed) Handbook of psychology and diabetes: A guide to psychological measurement in diabetes research and practice. Abingdon: Routledge. 1994; 111–32. ISBN: 9783718655625.

16. Ishii H. Development and psychometric validation of the Diabetes Therapy-Related QOL (DTR-QOL) questionnaire. J Med Econ. 2012; 15(3): 556–63. doi: 10.3111/13696998.2012.665111.

17. Pilla SJ, Meza KA, Schoenborn NL et al. A qualitative study of perspectives of older adults on deintensifying diabetes medications. J Gen Intern Med. 2023; 38(4): 1008–15. doi: 10.1007/s11606-022-07828-3.

18. Pilla SJ, Jalalzai R, Tang O et al. A national survey of physicians' views on the importance and implementation of deintensifying diabetes medications. J Gen Intern Med. 2024; 39(6): 992–1001. doi: 10.1007/s11606-023-08506-8.

19. Wrzal PK, Mohseni AA, Fournier C et al. Persons with diabetes and general/family practitioner perspectives related to therapeutic inertia in type 2 diabetes mellitus using qualitative focus groups and the theoretical domains framework: Results from the MOTION study. Can J Diabetes. 2022; 46(2): 171–80. doi: 10.1016/j.jcjd.2021.08.004.

20. Roldan Munoz S, Mol PGM, de Vries F et al. Perspectives of people with type 2 diabetes mellitus towards a decision aid assessing preferences of glucose-lowering drugs: The dilemma of choosing. Patient Prefer Adherence. 2025; 19: 215–34. doi: 10.2147/PPA.S486553.

21. Polonsky WH, Henry RR. Poor medication adherence in type 2 diabetes: Recognizing the scope of the problem and its key contributors. Patient Prefer Adherence. 2016; 10:1299–307. doi: 10.2147/PPA.S106821.

22. Beato-Víbora PI, Chico A, Moreno-Fernandez J et al. Transitioning between automated insulin delivery systems: A focus on personalisation. Diabetes Res Clin Pract. 2025; 222: 112070. doi: 10.1016/j.diabres.2025.112070.

23. Shubrook JH, Radin M, Ali SN et al. Preference for type 2 diabetes therapies in the United States: A discrete choice experiment. Adv Ther. 2022; 39(9): 4114–30. doi: 10.1007/s12325-022-02181-7.

24. Aroda VR, Rosenstock J, Wysham C et al.; LixiLan-L Trial Investigators. Efficacy and safety of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide in type 2 diabetes inadequately controlled on basal insulin and metformin: The LixiLan-L randomized trial. Diabetes Care. 2016; 39(11): 1972–80.doi: 10.2337/dc16-1495.

25. Weatherall J, Polonsky WH, Lanar S et al. When insulin degludec enhances quality of life in patients with type 2 diabetes: A qualitative investigation. Health Qual Life Outcomes. 2018; 16(1): 87. doi: 10.1186/s12955-018-0883-1.

26. Mekashaw Bayked E, Haile Kahissay M, Demeke Workneh B. The “Life-World” trip of type 2 diabetes patients with allopathic treatment options: A triangulated qualitative investigation. Ann Med. 2022; 54(1): 2714–24.doi: 10.1080/07853890.2022.2122552.